Corporate Governance

We have high standards for our employees and leadership. this helps us stay focused on our goals and maintain our responsibilities.

Committees & Charters


Board Committees

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on the committee names in the chart below.

Audit

James A. Cannon
Senator Wyche Fowler, Jr., J.D.
Scott Tarriff
Michael Weiser, M.D., Ph.D.

Compensation

Sir Murray Brennan, M.D.
Scott Tarriff
Michael Weiser, M.D., Ph.D.

Nominating

Sir Murray Brennan, M.D.
Senator Wyche Fowler, Jr., J.D.
Michael Weiser, M.D., Ph.D.
= Chair of the Board
= Chair
= Member
  Audit Compensation Nominating
Sir Murray Brennan, M.D.
Sir Murray Brennan, M.D.
Emeritus Chairman of Surgery, Memorial Sloan Kettering Cancer Center

Sir Murray Brennan, M.D., is the emeritus chairman of Memorial Sloan Kettering Cancer Center’s Department of Surgery and previously served as chairman since 1985.  Dr. Brennan has lectured and acted as a visiting professor throughout the world and has authored over 1000 scientific papers.  He has served as director of the American Board of Surgery, vice president of the American College of Surgeons, chairman of the American College of Surgeons Commission on Cancer, president of the Society of Surgical Oncology and president of the American Surgical Association, the oldest and most prestigious surgical association in the United States.  Dr. Brennan is a member of the National Academy of Sciences.  He was named Knight Grand Companion of the New Zealand Order of Merit and is the recipient of numerous honors and medals for his leadership of surgery and oncology worldwide.  

 
James A. Cannon
James A. Cannon
Chief Financial Officer and Vice Chairman, BBDO

James (Jim) Cannon is Vice Chairman, Chief Financial Officer and a member of the Board of Directors of BBDO Worldwide. In this capacity, he oversees the financial management of BBDO operations in 77 countries. Jim joined BBDO in 1967, was promoted to Chief Financial Officer of the agency in 1984, and was elected to its Board of Directors one year later. An integral member of the team that formed Omnicom via a unique three-agency merger of BBDO, DDB and Needham Harper & Steers, Jim became Comptroller of the new group (NYSE: OMC) and a member of its Board of Directors in 1986, a position he held through 2002. In 1987, he was appointed Director of Financial Operations of the Omnicom Group, serving in this capacity until early 1989 when he rejoined BBDO Worldwide as Executive Vice President and Chief Financial Officer. His return was concurrent with that of Allen Rosenshine who became Chairman and Chief Executive Officer of BBDO after heading Omnicom. Jim was promoted to Vice Chairman of the agency in 1990. Jim is a graduate of Pace University and served in the US Marine Corps.

   
Senator Wyche Fowler, Jr., J.D.
Senator Wyche Fowler, Jr., J.D.
Former US Senator and Ambassador to Saudi Arabia

Senator Wyche Fowler, Jr. served for 16 years in the United States Congress. In the US Senate, he served as assistant floor leader, helping mould a bipartisan consensus for major public policy issues. Senator Fowler was a member of the Senate Appropriations, Budget, Energy and Agriculture Committees. First elected to the US House of Representatives, he was a member of the Ways and Means and Foreign Affairs Committees, as well as the Select Committee on Intelligence. President Clinton appointed Senator Fowler US Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. On his return, the FBI awarded him its highest civilian honor, The Jefferson Cup, for his assistance in combating terrorism and for helping solve terrorism crimes against the US military in Saudi Arabia. He was named Lion of Judah by the State of Israel for successfully freeing Soviet Jew Yakov Gluzman. Senator Fowler is now engaged in an international business and law practice, and also serves as Chairman of the Board of the Middle East Institute, a non-profit foundation in Washington, DC.

 
Scott Tarriff
Scott Tarriff
President and CEO, Eagle Pharmaceuticals, Inc.

Scott Tarriff is the founder of Eagle Pharmaceuticals, Inc., a publicly traded company, and has served as President and Chief Executive Officer and as a member of its board of directors since its inception. Mr. Tarriff has grown Eagle Pharmaceuticals from a privately financed pharmaceutical development company to an established, publicly traded, specialty pharmaceutical company. Prior to forming Eagle, Mr. Tariff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par's board of directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and previously served on the board of directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College.

 
Michael Weiser, M.D., Ph.D.
Michael Weiser, M.D., Ph.D.
Founder and Co-Chairman of Actin Capital, LLC and Actin Biomed

Dr. Weiser is currently founder and co-chairman of Actin Biomed, a New York based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine. He performed his post-graduate medical training in the Department of Obstetrics and Gynecology at New York University Medical Center. Dr. Weiser also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and received his B.A. in Psychology from University of Vermont. Dr. Weiser is a member of The National Medical Honor Society, Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology and Association for Research in Vision and Ophthalmology. In addition, Dr. Weiser has received awards for both academic and professional excellence and is published extensively in both medical and scientific journals. Dr. Weiser currently serves on the board of directors of Chelsea Therapeutics International, Emisphere Technologies, Inc and Ziopharm Oncology, Inc. as well as several privately held companies.

= Chair of the Board = Chair = Member

Committee Charters
Title View
Audit Committee Charter
PDF
37.6 KB
Compensation Committee Charter
PDF
49.3 KB
Corporate Governance and Nominating Committee Charter
PDF
83.9 KB